OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership ...

GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease. The new partnership, announced Wednesday morning, will see GSK access Ochre’s ...

(Reuters) -GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on Monday, a surprise switch as the British firm looks to rev up its ...

British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech ...

LONDON, June 25 (Reuters) - Drugmakers Bharat Biotech and GSK (GSK.L), opens new tab will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they ...

SHANGHAI/WASHINGTON (Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...

(Reuters) -GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and ...

GSK GSK0.37%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...